1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow BNT162b5: new trials by email Literature Review of BNT162b5 trials Research Report on BNT162b5
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent - Systemic Allergic Reaction | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2021-09-08 | 2023-10-16 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · COVID-19 (1) · Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Pemphigus (1) · Scleroderma, Systemic (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2)
United States (2)
Amit Bar-Or, MD, FRCP (1) · Dinesh Khanna, MBBS, MSc (1) · Judith A. James, MD, PhD (1) · Meggan C. Mackay, MD, MS (1) · Natasha Mckerran Ruth, MD (1) · Pamela A Guerrerio, M.D. (1) · Stacy Ardoin, MD (1) · Tracey Wright, MD (1) · Virginia Pascual, MD (1)